MEDI GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics
- Written by PR Newswire
SEOUL, South Korea, Dec. 17, 2025 /PRNewswire/ -- MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic diseases, announced today that it has entered into a Catalyze agreement with Eli Lilly and Company (Lilly) to advance a next-generation therapeutic for obesity.















